SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexion Pharmaceuticals, Inc. (ALXN)

NEW YORK, May 23, 2017

The investigation concerns whether Alexion and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 8, 2017 Alexion's São Paulo offices were raided as part of an investigation into the Company's business practices. Local law enforcement officials allege that Alexion is involved in a scheme wherein the Company, with the aid of a local patient association, subsidized lawsuits for patients to get access to its drug via Brazil's national health system. Following this news, Alexion stock dropped $4.34 per share or 3.37% to close at $124.48 on May 8, 2017. 

On May 16, 2017, Ludwig Hantson, Alexion's CEO, confirmed that the police raided its São Paulo offices and notified shareholders that it is reviewing its spending and compliance practices.  Following this news, Alexion stock dropped $4.15 per share or 3..45%, to close at $116.15 on May 17,2017.

Then on May 23, 2017, Alexion revealed the resignation of its Chief Financial Officer Dave Anderson, effective at the end of August.  Following this news, Alexion stock has dropped as much as $9.13 per share or 7.91% during intraday on May 23, 2017.

If you are aware of any facts relating to this investigation, or purchased shares of Alexion, you can assist this investigation by visiting the firm's site: www.bgandg.com/alxn. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.